



Rare Informs the Common

On June 22, 2016, Lysogene's Founder and CEO, Karen Aiach, delivered an inspiring keynote speech at "Precision Medicine 2016: Rogue Therapeutics", hosted for the second year by the Department of Biomedical Informatics at Harvard Medical School in Boston, Mass. The conference, attended by 500 industry leaders, highlighted individuals who are blazing new paths, going rogue through non-standard protocol to find therapeutics that target rare, and at times misdiagnosed, diseases.

In her keynote speech, Karen recounted discovering her daughter's condition, Sanfilippo Syndrome A, finding resources and treatments for it, and eventually founding Lysogene to develop a gene therapy treatment for this brutal disease. Karen also gave an overview of the impact of rare diseases and the potential for developing gene therapy programs to treat these life-threatening conditions. She also shared her belief that a patient-focused approach would open the way for medical progress and create new medical knowledge to treat rare diseases. Karen's belief and motivation have led to Lysogene's recent accomplishments, including its successful Phase I/II clinical trial, a Series A funding of €16.5 million, a partnership with the University of Massachusetts Medical School and Auburn University to expand the company's clinical expertise, and the expansion of the company. "It is our responsibility and goal to work together with patients, industry experts, clinicians, policymakers, and regulators to find therapeutics to treat patients with rare diseases and help them improve their health and fight for life," said Karen.

Karen's keynote speech at "Precision Medicine 2016: Rogue Therapeutics" can be found [here](#). For more information about Lysogene, please visit <http://www.lysogene.com/>.

